P1149: COMPARISON OF THE EFFICACY OF EPCORITAMAB VERSUS CHIMERIC ANTIGEN RECEPTOR THERAPIES, POLATUZUMAB-BASED REGIMENS, AND TAFASITAMAB-BASED REGIMENS
Allison Rosenthal,
Monika Jun,
Javier Munoz,
Tongsheng Wang,
Alex Mutebi,
Anthony Wang,
Shibing Yang,
Kojo Osei-Bonsu,
Brian Elliott,
Anupama Kalsekar,
Fernando Rivas Navarro,
Andrew Ip
Affiliations
Allison Rosenthal
1 Mayo Clinic, Phoenix, United States
Monika Jun
2 Genmab US, Inc., Princeton, United States
Javier Munoz
1 Mayo Clinic, Phoenix, United States
Tongsheng Wang
2 Genmab US, Inc., Princeton, United States
Alex Mutebi
2 Genmab US, Inc., Princeton, United States
Anthony Wang
3 AbbVie, Inc, North Chicago, United States
Shibing Yang
2 Genmab US, Inc., Princeton, United States
Kojo Osei-Bonsu
3 AbbVie, Inc, North Chicago, United States
Brian Elliott
2 Genmab US, Inc., Princeton, United States
Anupama Kalsekar
2 Genmab US, Inc., Princeton, United States
Fernando Rivas Navarro
4 Genmab A/S, Copenhagen, Denmark
Andrew Ip
5 Hackensack University Medical Center, Hackensack, United States
